Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
5 Family SUVs for 2024: Which One Accommodates Your Family's Needs\uff1f - 2The Best Cell phone Brands for Tech Lovers
- 3Indian Health Service is digging out of decades-old construction backlog for medical buildings
- 4Police arrest 18 as anti-war protests spread across Tel Aviv, Haifa, Jerusalem
- 5Must-See Attractions in Washington, D.C.
- IDF strikes Shiraz petrochemical site, releases footage of attacks on Iranian air defenses
- What do teens and tweens want for the holidays? E-bikes, gift cards and lip tints.
- Which salad do you believe is a definitive group pleaser? Vote!
- Shakira's 2026 'Las Mujeres Ya No Lloran' U.S. Tour: How to get tickets, prices, dates and more
- 7 Straightforward Moves toward Move Information from Your Old Cell phone to Your New One: A Thorough Aide
- Astrophotographer captures spectacular photo of Antennae Galaxies dueling in deep space
- Vote In favor of Your Number one Kind Of Food Conveyance Administration
- South Africa pushes for $200B investment
- Instructions to Amplify Certifiable Experience While Chasing after an Internet Advertising Degree
